We’re using cookies to give you the best experience possible of Essity.com. Read more about the cookies we use and how to change your settings:
Essity’s Annual General Meeting was held today at Stockholm Waterfront Congress Center in Stockholm, Sweden
Hygiene and health company Essity is strengthening its offering in incontinence products through the acquisition of the Dutch company Novioscan. The company develops a wearable ultrasound technology that monitors the bladder and enables continence control. The purchase price is approximately SEK 70m (EUR 6.5m) on a debt-free basis.
As a consequence of the situation concerning the coronavirus pandemic, Essity’s Nomination Committee has decided to withdraw its proposal that Essity’s Annual General Meeting on April 2, 2020 approve an increase in Board fees (item 11 on the agenda).
At the Annual General Meeting on April 2, 2020, the Board of Directors will propose that the Meeting postpones a decision regarding the dividend for 2019 until an Extraordinary General Meeting no later than November 2020. The Board of Directors’ previous assessment of a dividend of SEK 6.25 per share remains. The final assessment on the size of the dividend will, however, be taken at a later date when the effects of the current COVID-19 pandemic are better understood.
Essity’s Interim report for the first quarter of 2020 will be published on April 23 at approximately 7:00 CET. In conjunction with publication, a telephone and web presentation will be held at 9:00 CET where President and CEO Magnus Groth will present and answer questions.
Hygiene and health company Essity has today published its Annual and Sustainability Report for 2019 on www.essity.com (https://www.essity.com/investors/)
The continued spread of the coronavirus remains difficult to assess with any certainty. Essity is carefully monitoring developments.
Hygiene and health company Essity has signed an agreement to acquire 75% of the Swedish medical solutions company ABIGO Medical AB. The company as a whole is valued at SEK 900m on a debt-free basis. ABIGO Medical AB develops, manufactures and markets products including the Sorbact[® ]technology, which is a clinically established innovation for advanced wound care. Jan G. Smith will retain a 25% stake in the company and remain as chairman of the board.
Notice is given to the Shareholders of Essity Aktiebolag (publ) (”Essity”) of the Annual General Meeting of Shareholders to be held on Thursday April 2, 2020 at 3 p.m. at Stockholm Waterfront Congress Centre, Nils Ericsons Plan 4, Stockholm (registration from 1.30 p.m.).